Background and aims: Despite numerous shared susceptibility loci between Crohn's disease and ulcerative colitis, the prevalence of family history among ulcerative colitis patients is not well-established and considered to be less prevalent. A systemic review and meta-analysis were conducted to estimate the prevalence of family history of inflammatory bowel disease in ulcerative colitis patients, and its effect on disease outcomes. Methods: PubMED was searched to identify studies reporting the prevalence of family history of inflammatory bowel disease among ulcerative colitis patients. Definitions of family history, study type, and subtypes of family history prevalence were abstracted, as were disease outcomes including age at ulcerative colitis diagnosis, disease location, surgery and extraintestinal manifestations. Pooled prevalence estimates were calculated using random effects models. Results: Seventy-one studies (86,824 patients) were included. The prevalence of a family history of inflammatory bowel disease in ulcerative colitis patients was 12% (95% confidence interval [CI] 11 to 13%; range 0-39%). Family history of ulcerative colitis (9%; 22 studies) was more prevalent than Crohn's disease (2%; 18 studies). Patients younger than 18 years of age at time of diagnosis had a greater family history of inflammatory bowel disease (prevalence 15%, 95% CI: 11-20%; 13 studies). There were no differences in disease location, need for surgery, or extraintestinal manifestations among those with a family history, although very few studies reported on these outcomes.
Introduction
Ulcerative colitis (UC) is the most common form of inflammatory bowel disease (IBD), followed by Crohn's disease (CD). IBD is thought to have a multifactorial etiopathogenesis involving environmental and genetic factors. Family history is a composite of shared environmental exposures and genetic factors. An increased risk of IBD among family members was first suspected nearly 50 years ago; in more recent studies of family history in IBD, a greater proportion of CD patients have a family history than UC patients. [1] [2] [3] This difference is most pronounced in twin studies, where participants have shared genes and similar early life environments. Among monozygotic twins, concordance for IBD is 50 to 60% in CD compared with 6 to 18% in UC. 4 Concordance rates for dizygotic twins are 12% in CD and 5% in UC. 4 In recent years, genome-wide association studies (GWAS) have identified over 160 loci associated with IBD. 5 Some studies have shown that as many as 47 loci are predominantly associated with UC, 71 loci are predominantly associated with CD [5] [6] [7] [8] and 28 loci are shared between UC and CD. 8 Despite numerous shared susceptibility loci between CD and UC, the prevalence of family history among UC patients is not well-established and considered to be less prevalent.
Therefore, we aimed to estimate the prevalence of a family history of IBD among patients with UC. We also aimed to examine the relationship between family history with age at diagnosis, disease severity and location and extraintestinal manifestations.
Materials and methods

Data sources and search strategy
We searched PubMed in September 2010 with no restriction to publication date using the following search strategy: ("ulcerative colitis" OR "UC" OR "IBD" OR "inflammatory bowel disease") AND ("family history" OR "family" OR "familial" OR "kindred" OR "twin" OR "inherited" OR "hereditary" OR "sibling" OR "parents") NOT ("rat" OR "mouse" OR "murine").
Study selection
Two reviewers independently reviewed titles and abstracts. We included titles that appeared to report original research on IBD. Only one reviewer had to identify a study as potentially relevant to progress to the abstract review. We included abstracts that either explicitly reported on family history or were original research (including trials, observational studies, and genetics studies) that were likely to include a table on patient characteristics that might include family history. Both reviewers had to agree that the study was eligible at the abstract level for the full text to be reviewed. To be eligible for inclusion during the full text review, the study was required to report on the family history of IBD, UC or CD among UC patients. All studies that met the inclusion criteria at the full-text review had data abstracted by one reviewer with a second reviewer confirming the data abstraction.
As a quality control measure, a senior investigator reviewed 100 publications at the title and abstract levels and confirmed the inclusion/exclusion of studies with the reviewers to ensure that consistent inclusion and exclusion criteria were applied. Conflicts between reviewers during the abstract, full text review and data abstraction were resolved by consensus including a senior investigator.
Outcomes of interest
The primary outcome was prevalence of a family history of IBD. Among studies that reported a primary outcome, secondary outcomes were also abstracted if the results were provided among patients with and without a family history of IBD. Secondary outcomes included the prevalence of subtypes of IBD including a family history of UC, CD and indeterminate colitis. Additional secondary outcomes included age at diagnosis, disease location, need for surgery, and extra-intestinal manifestations.
Study characteristics that may modify the outcomes
Study design, definitions of family history and the populations included in the study may modify the observed IBD family history prevalence. We collected information on these potential modifiers so that we could quantify the degree to which these definition and inclusion criteria affected our findings. Data on the definition of family history (first-degree, second-degree, distant relative, or not reported) and study type (cohort [including trial], casecontrol, and cross-sectional) were abstracted. First-degree relatives were defined as parents, children, or siblings. Second-degree relatives were defined as grandparents, aunts, and uncles but could include parents, children and siblings. Distant relatives were defined as all other types of family relatedness, while a "not reported" category was created for the remaining subset of studies did not provide a definition of family history at all. We did not assess for tests of publication bias, as the majority of included studies were not designed to assess family history and the data was abstracted from demographics tables. For the few studies examining the relationship between family history and outcomes, no meta-analyses were performed.
We hypothesized that younger age at diagnosis may be associated with a greater prevalence of family history. When available, we based this on age at diagnosis and age at enrollment when age at diagnosis was not reported. A study was classified as youth age at onset when the maximum age of the study population was 18 years or less. A study was considered adult for all studies that included any adults at onset, even if some participants may have been diagnosed under the age of 18. When maximum age was not reported, the mean or median age was used to classify the study.
Data extraction
Data extraction was completed by two reviewers. One reviewer extracted relevant information from each included study: type of study, study characteristics (design, year of publication, disease location, family history definition, data collection source), population characteristics (percent of UC vs. CD patients), family history prevalence, and the secondary outcomes of interest. Secondary outcomes were abstracted only if the prevalence of family history was reported. A second reviewer carefully reviewed the first reviewer's data abstraction for errors. Any differences in opinion were resolved through consensus and input from a senior investigator. Throughout the analysis and writing process, data were examined for plausibility and if data abstraction errors were detected, they were fixed.
Statistical analyses
Pooled prevalence estimates for prevalence of family history of IBD, CD and UC were calculated by fitting random effects models using the method of DerSimonian and Laird. We performed stratified analyses of items that may cause heterogeneity such as study design and definition of family history. All analyses were conducted using Stata, version 11. Analyses were performed stratified by the study characteristics of interest. Confidence intervals were calculated for each estimate as few studies reported confidence intervals in the manuscripts.
Secondary outcome measures including need for surgery, extra-intestinal manifestations and concordance of disease type were not reported frequently enough or with the same definition to allow meta-analyses. Instead, we describe the observed findings from the few studies that provided information for each of these outcomes.
Results
Study search and selection
The search strategy identified 2179 citations (Fig. 1 ). Of these, 1934 were excluded after examining the title and abstract. We excluded 12 studies that may have been relevant but were not in English. Study populations that were reported more than once (in two separate articles) were included by choosing the most recent article. After examining the full texts of 246 articles, 71 articles met the inclusion criteria (Table 1) . The number of patients represented by these 71 articles was 86,824. Of these, 12 were prospective cohort studies, 29 were retrospective cohort studies, 20 were case-control studies, and 12 were cross-sectional studies. Two studies were reported as both retrospective and prospective cohort Figure 1 Flow diagram of assessment of studies in systematic review. studies, 33, 33 and 1 study was reported as both a retrospective and case-control study. 87 No trial or study that aimed to measure genetic risk factors was included.
The source of information used to identify family history for the studies included chart review (22 studies), questionnaires (31 studies), interviews (17 studies), and registry data (3 studies); nine studies did not report an information source; ten studies contained more than one data source (Table 1) .
Family history of IBD among UC patients
When the 71 studies were pooled, the overall prevalence of a family history of IBD in UC patients was 12% (95% CI: 11-13%; n = 86, 824, I 2 = 0.002; range 0-39%) (Fig. 2) . We found more studies reporting the prevalence of a family history among first-degree relatives of UC patients compared with second-degree or distant relatives of UC patients, but the prevalence was similar whether the family history type was for first-degree relatives, second-degree relatives, distant relatives, or relatives for which the classification was not reported. Study design (cohort, case-control, crosssectional) had little effect on prevalence estimate, and neither did the method of obtaining family history (chart review, questionnaire, or interview; data not shown).
Age at diagnosis and prevalence of family history
The prevalence of a family history of IBD was calculated by the age at UC diagnosis or study enrollment among patients included in the studies. Thirteen studies exclusively included participants younger than the age of 18 at time of diagnosis or enrollment (Fig. 3) . Twenty-eight studies included adults at the time of the study (some of whom may have been pediatric-onset cases) and 31 studies did not report age at diagnosis. We found that studies of UC patients age 18 or younger at enrollment were more likely to have a family history of IBD (prevalence 15%, 95% CI 11-20%, I 2 = 0.0051) than studies of UC patients who were older at enrollment (prevalence 11%, 95% CI 9-13%, I 2 = 0.0024). Among the 31 studies that did not report age at diagnosis, the prevalence of a family history of IBD among UC patients was 12% (CI 10-14%, I 2 = 0.0024; data not shown).
Family history of UC compared with CD among UC patients
Twenty-two studies (n = 18,895) reported the prevalence of a family history of UC among UC patients, with an overall prevalence of 9% (CI 3-15%). 18 studies (n = 17,262) reported the prevalence of a family history of CD among UC patients, with an overall prevalence of 2% (CI 1-2%).
There were no studies that reported data on family history of indeterminate colitis among UC patients.
Family history of IBD and disease location, need for surgery, and extra-intestinal manifestations
Disease location, need for surgery, and extra-intestinal manifestations among UC patients with and without a family history of IBD were reported in seven studies. 34, 47, 66, 70, 72, 84, 93 There were wide ranges in estimates across studies with little difference in the secondary outcomes between familial and sporadic UC patients. For example, of the five studies reporting data on disease location, four reported a trend toward greater prevalence of pancolitis in patients without a family history of IBD (22-68% pancolitis with family history; 34-76% pancolitis without family history); statistical tests were not conducted in any of these studies. 34, 46, 65, 69 Heterogeneity in definitions for these outcomes prevented meta-analysis.
Discussion
Among 71 studies involving 86,824 patients, 12% of UC patients have a family history of IBD. Studies with UC patients diagnosed at age 18 or younger reported greater prevalences of a family history of IBD than other studies. UC patients with a family history of IBD may have a higher family history of UC (9%) compared with CD (2%).
The finding that younger UC patients are more likely to have a family history of IBD compared with older UC patients supports existing evidence suggesting that those with a family history of UC have disease onset at a younger age compared with their parents. 19 This finding previously spurred interest in genetic anticipation as a potential contributor to a unique clinical phenotype in UC. 20, 21 While observational or ascertainment biases might have accounted for the appearance of genetic anticipation in earlier studies, 22, 23 the study by Bengtson suggested that genetic anticipation may indeed play a role in UC. 19 Whether genetic anticipation is occurring or not, the finding that younger UC patients are more likely to have a positive family history of IBD may be important in further research seeking to identify patterns of heritability in polygenetic diseases like IBD.
The apparent increase in family history prevalence may be related to the fact that the actual incidence of IBD is increasing, perhaps due to both genetic and environmental factors, and that increased recognition of IBD family history as an important component of the care of patients and their families has led to more persistent questioning and data gathering by clinicians, and increased interest from researchers. 4, 85 GWAS may hold the key for further elucidating our understanding of the polygenic pathways of IBD, including which genes may confer a familial risk.
1,5,9,10 A recent study by Jostins and collaborators showed that there are many shared loci between UC and CD; our study found a higher concordance of a UC family history among UC patients compared to a CD family history, which may suggest that specific loci influence the type of IBD. 5 Our study also showed no apparent difference in family history prevalence based on degree of family relatedness; this may reflect the variable penetrance of genetic loci suspected to cause UC, or predispose an individual to developing UC. Understanding the UC phenotypes that occur within families may help prioritize the linkage of identified loci with phenotypic variation. Even if gene mapping in IBD ends up having limited clinical application given the polygenetic pathophysiology of the disease, not to mention the uncertain role environmental factors play in pathogenesis, knowing the true overall prevalence of UC in at-risk populations like family members might help clinicians and researchers gauge how Median age at time of study, rather than mean age at time of study. much time and resources should be invested in clinical surveillance or allow clinicians to use family history as a biomarker until clinically useful genetic panels are developed. There were limitations in the identified data and our process. Table 1 shows the complete listing of included studies; as with any large sample of studies, confounders such as differences in study design, number of patients, year(s) of study duration, and location exist. Furthermore, many studies did not define family history or its source. We did, however, stratify our results based the family history types and sources that were reported, and we found no statistical difference in family history prevalence based on study data source or study type. Future studies should clarify how data on important risk factors, like family history, are collected.
Lack of reporting of time-to-event data prevented the examination of the role that family history may play in the natural history of disease. If family history modifies disease course, targeted treatment strategies could be examined for those with a family history. Stratification of family history by age was not performed in any study, so we classified studies according to age at enrollment instead of age at diagnosis. Family history among adult-onset UC patients may be even lower than the observed 11% due to the inclusion of an unknown number of youth-onset UC patients in some of these studies. Finally, we were unable to locate studies containing sufficient data with similarly reported outcomes to perform additional meta-analyses examining the relationship between family history and concordance of location, need for surgery, or presence of extra-intestinal manifestations. [11] [12] [13] [14] [15] [16] [17] [18] 61, 65, 79 Although a family history of IBD among patients with a diagnosis of UC or CD has been known to exist for over 30 years, most previous studies have focused on family history in patients with CD rather than UC. We found that the prevalence of a family history of IBD among UC patients was 12%. This prevalence is robust to definitions of family history and study design. Younger UC patients are more likely to have a family history of IBD compared with older UC patients. UC patients were more likely to have a family history of UC compared with CD. There remains very little information on the role of family history on need for surgery, extra-intestinal manifestations, concordance of disease type (UC, CD, or indeterminate colitis), and disease location of UC as it relates to family history. Future studies should seek to identify the concordance of phenotype and age at diagnosis in familial UC.
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